Clinical trial
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian…
NCT00016224 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00016224 |
|---|---|
| Title | Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer |
| Official title | Phase II Trial of Thalidomide in Patients With Ovarian Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | thalidomide |
| Start date | Jan 1, 2001 |
| Primary completion | Mar 1, 2004 |
| Completion | Mar 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: